Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to ...

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Recursion strengthened its AI focus by snapping up two companies in the AI-driven drug discovery space.

HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding ...

The Verdict Recursion Pharmaceuticals offers a compelling investment for exposure to AI-driven drug discovery, backed by a strong balance sheet.

Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.

Recursion is not intrinsically better or worse than loops—each has advantages and disadvantages, and those even depend on the programming language (and implementation).